Pfizer (NYSE:PFE) Price Target Raised to $30.00

Pfizer (NYSE:PFE) had its price target boosted by Citigroup from $27.00 to $30.00 in a report published on Wednesday morning,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also commented on PFE. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. HSBC raised their target price on Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, September 10th. BMO Capital Markets reduced their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Bank of America decreased their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Finally, Scotiabank increased their price target on shares of Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. Six research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $30.39.

Pfizer Stock Performance

Shares of PFE stock traded down $0.50 during trading on Wednesday, reaching $29.38. 48,291,518 shares of the company’s stock traded hands, compared to its average volume of 30,697,644. The firm’s 50-day moving average is $28.74 and its 200 day moving average is $26.90. The company has a market capitalization of $167.46 billion, a P/E ratio of 41.97, a PEG ratio of 2.08 and a beta of 0.31. Pfizer has a 1 year low of $23.62 and a 1 year high of $31.44. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.13. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $16.58 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same period in the previous year, the business earned $0.87 EPS. Pfizer’s revenue was down .4% compared to the same quarter last year. Equities research analysts expect that Pfizer will post 3.03 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 annualized dividend and a yield of 5.9%. Pfizer’s dividend payout ratio (DPR) is currently 245.71%.

Institutional Investors Weigh In On Pfizer

Several hedge funds have recently bought and sold shares of PFE. Retirement Wealth Solutions LLC increased its holdings in shares of Pfizer by 144.6% in the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 509 shares during the last quarter. Keb Asset Management LLC bought a new stake in shares of Pfizer during the 2nd quarter worth $26,000. Field & Main Bank purchased a new position in Pfizer in the second quarter worth $27,000. Bullseye Investment Management LLC purchased a new position in Pfizer in the second quarter worth $28,000. Finally, Timbuktu Capital Management LLC bought a new position in Pfizer in the second quarter valued at $29,000. 68.36% of the stock is currently owned by institutional investors.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s third-quarter results beat analyst expectations, and the company raised its 2026 earnings outlook. Reports also highlighted momentum from newer products, although margin pressure remains a concern. Pfizer Q3 Earnings Rebuild Confidence As New Drugs Gain Ground
• Positive Sentiment: Guggenheim reiterated a Buy view and raised its price target to $33 from $31, signaling potential upside in the analyst’s view. Pfizer Receives a Buy from Guggenheim
• Neutral Sentiment: Pfizer updated an ulcerative-colitis treatment-pattern study and advanced a Phase 3 RSV-vaccine study in high-risk children. The announcements describe ongoing research; no efficacy or safety results were provided in the summaries. Pfizer Advances Phase 3 RSV Vaccine Study
• Negative Sentiment: DZ Bank cut its rating on Pfizer from Buy to Hold, a less favorable view that may temper optimism from other analysts. Pfizer also lagged in a news report focused on Moderna’s earnings-driven gain, though that comparison is not a change in Pfizer’s fundamentals. DZ Bank recommendations Moderna Climbs as Pfizer Dips

About Pfizer